Showing posts with label ExonHit. Show all posts
Showing posts with label ExonHit. Show all posts
Tuesday, October 18, 2011
Exonhit : Research Agreement With Pfizer to Identify Alzheimer’s Disease Biomarkers
October 10, 2011 - Exonhit (Paris:ALEHT) announced that it has entered into a research agreement with Pfizer Inc. for the identification of new Alzheimer’s disease (AD) biomarkers using Exonhit’s Genome-Wide SpliceArray™ (GWSA) platform.
As part of the agreement, the two companies will jointly conduct a pilot study using Exonhit’s GWSA platform to gain insight on AD molecular markers associated with clinical parameters. More specifically, the purpose of the research work is to seek to identify progression and other biomarkers that could segregate healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD. Test samples for the study will be provided by Pfizer from a number of subjects in each of these three groups over a period of time.
“Today’s announcement further demonstrates the interest in the potential of our GWSA discovery platform,” said Loïc Maurel M.D., President of Exonhit’s Management Board. “We are excited to collaborate with Pfizer and we hope that this study will identify new Alzheimer’s biomarkers and hence lead to the potential development of prognostic tests for patients”...
[...]
...About Exonhit Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheimer’s disease. Exonhit has a balanced development strategy with internal development programs and strategic collaborations, in particular with Allergan. Exonhit is headquartered in Paris, France and has a U.S. subsidiary in Gaithersburg, Maryland. The Company is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index... [PDF] Exonhit's Press Release - PDF du communiqué de presse Exonhit -
As part of the agreement, the two companies will jointly conduct a pilot study using Exonhit’s GWSA platform to gain insight on AD molecular markers associated with clinical parameters. More specifically, the purpose of the research work is to seek to identify progression and other biomarkers that could segregate healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD. Test samples for the study will be provided by Pfizer from a number of subjects in each of these three groups over a period of time.
“Today’s announcement further demonstrates the interest in the potential of our GWSA discovery platform,” said Loïc Maurel M.D., President of Exonhit’s Management Board. “We are excited to collaborate with Pfizer and we hope that this study will identify new Alzheimer’s biomarkers and hence lead to the potential development of prognostic tests for patients”...
[...]
...About Exonhit Exonhit (Alternext: ALEHT) is a biotech company, focused on personalized medicine, which develops targeted innovative therapeutic and diagnostic products, in oncology and Alzheimer’s disease. Exonhit has a balanced development strategy with internal development programs and strategic collaborations, in particular with Allergan. Exonhit is headquartered in Paris, France and has a U.S. subsidiary in Gaithersburg, Maryland. The Company is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index... [PDF] Exonhit's Press Release - PDF du communiqué de presse Exonhit -
Friday, March 28, 2008
ExonHit : EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans
Scopolamine interferes with the transmission of nerve impulses by acetylcholine, a substance to which it is structurally similar, thus depressing nervous system activity. Cognitive impairment due to central cholinergic dysfunction, or scopolamine administration, is measurable through electroencephalography (EEG) changes under both nonstimulus and stimulus conditions. A number of studies indicate that EEG is a sensitive measure of acetylcholine's activity and of the induced alterations elicited by scopolamine. In addition, scopolamine-induced EEG changes have been considered as possible biomarkers for AD as the impairment acetylcholine's activity is one of the landmarks of this disease... ExonHit Therapeutics' Press Release -
Thursday, December 27, 2007
ExonHit Therapeutics, Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease
20 December 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease . EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss... ExonHit's Press Release -
Monday, December 3, 2007
EXONHIT , A PROTOTYPE TO DETECT ALZHEIMER'S DISEASE FROM BLOOD
Paris, France - November 8, 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, has completed a prototype of the first blood-based Alzheimer's disease test. The company expects to have this test certified and to provide it as a service in its GLP (Good Laboratory Practices) compliant laboratories to the pharmaceutical industry as early as 2009... ExonHit's Press Release - Communiqué de Presse ExonHit -
Subscribe to:
Posts (Atom)